What is the stepwise management of epistaxis in an adult, including first‑line compression, topical vasoconstrictors, cauterization, nasal packing, and anticoagulant considerations?

Stepwise Management of Epistaxis in Adults

Initial Compression (First-Line)

Apply firm, continuous pressure to the soft lower third of the nose for a full 10–15 minutes without checking for cessation—premature release is the single most common cause of treatment failure. 1

• Position the patient seated upright with the head tilted slightly forward to prevent blood from entering the airway or stomach 1
• Instruct the patient to breathe through the mouth and expectorate blood rather than swallow it 1
• Compression alone resolves the vast majority of anterior epistaxis cases 1
• This maneuver can be performed by the patient, caregiver, or clinician 1

Topical Vasoconstrictors (Second-Line)

If bleeding persists after 10–15 minutes of proper compression, apply two sprays of oxymetazoline or phenylephrine into the bleeding nostril, then resume firm compression for an additional 5–10 minutes. 1

• Vasoconstrictor application stops bleeding in 65–75% of emergency department cases 1, 2
• Obtain a baseline blood pressure before vasoconstrictor use because approximately one-third of epistaxis patients have undiagnosed hypertension, and vasoconstrictors carry increased cardiac or systemic complications in this population 1
• Avoid repeated or prolonged use of topical vasoconstrictors, as this can precipitate rhinitis medicamentosa and worsening nasal obstruction 1

Cauterization (Third-Line)

When a focal bleeding point is identified on anterior rhinoscopy, anesthetize the site with topical lidocaine and cauterize only the active bleeding point. 1

• After clot removal by suction or gentle nose blowing, perform anterior rhinoscopy to identify the bleeding source 1
• If anterior rhinoscopy fails to locate the source, proceed immediately to nasal endoscopy, which localizes the bleeding site in 87–93% of cases 1, 2
• Electrocautery is superior to chemical cauterization, with recurrence rates of 14.5% versus 35.1% 1, 2
• Never perform bilateral simultaneous septal cautery—this markedly increases the risk of septal perforation 1

Nasal Packing (Fourth-Line)

Reserve nasal packing for patients who continue bleeding after 15–30 minutes of proper compression combined with vasoconstrictors, have life-threatening hemorrhage, or have a suspected posterior bleeding source. 1

Packing Material Selection Based on Anticoagulation Status

• For patients on anticoagulants or antiplatelet medications, use only resorbable/absorbable packing materials (Nasopore, Surgicel, Floseal) to minimize trauma during removal 1
• For patients without bleeding-risk factors, either resorbable or non-resorbable materials may be used 1
• After packing placement, instruct patients to apply saline nasal spray frequently throughout the day to keep packing moist 1

Anticoagulant Considerations

Do not discontinue anticoagulant or antiplatelet agents before attempting first-line local measures (compression, vasoconstrictors, cautery, packing) unless hemorrhage is life-threatening. 1

Continuation of Antiplatelet Therapy

• Continue aspirin in patients at high cardiovascular risk (recent myocardial infarction or coronary stents) because survival benefits outweigh bleeding risks 1
• For NSAIDs, standard epistaxis alone is not an indication to stop; discontinue only if bleeding cannot be controlled with local measures 1
• Most epistaxis resolves with local measures alone, making premature NSAID discontinuation unnecessary 1

Reversal Strategies (Life-Threatening Hemorrhage Only)

Anticoagulant	Reversal Agent	Key Details
Warfarin	4-factor prothrombin complex concentrate (PCC), fresh frozen plasma, vitamin K	4-factor PCC provides faster INR correction and requires smaller infusion volume [1]
Dabigatran	Idarucizumab	Specific reversal agent [1]
Apixaban	Andexanet alfa (400 mg IV bolus over 15 min, then 480 mg infusion over 2 hr for low-dose; 800 mg bolus over 30 min, then 960 mg over 2 hr for high-dose) OR 2,000 units 4-factor PCC if andexanet unavailable	[1]
Rivaroxaban, edoxaban	4-factor PCC	[1]
Unfractionated heparin/LMWH	Protamine sulfate	[1]
Clopidogrel, prasugrel, ticagrelor	Platelet transfusion	Effectiveness depends on timing of last dose [1]

Timing of Anticoagulation Resumption

• Restart anticoagulation within 24–48 hours after confirmation of hemostasis, balancing thrombotic and bleeding risks on an individual basis 1

Advanced Interventions (Refractory Cases)

For persistent or recurrent bleeding not controlled by packing or cautery, evaluate candidacy for surgical arterial ligation or endovascular embolization. 1

• Endoscopic sphenopalatine artery ligation achieves a 97% success rate compared with 62% for conventional packing 1, 2
• Endovascular embolization has an 80% success rate with recurrence rates <10% versus 50% for nasal packing 1, 2
• Refer to otolaryngology when bleeding persists despite appropriate nasal packing or after three unsuccessful packing attempts 1

Prevention of Recurrence

After hemostasis, apply petroleum jelly or lubricating agents to the nasal mucosa 2–3 times daily to prevent recurrence. 1

• Use saline nasal sprays frequently throughout the day to keep nasal mucosa moist 1
• Recommend a humidifier in dry environments to prevent fragile, hyperemic nasal mucosa 1, 3
• Avoid nasal manipulation, vigorous nose-blowing, and nasal decongestants for at least 7–10 days after treatment 1

Red-Flag Signs Requiring Immediate Escalation

• Active bleeding despite correctly placed nasal packing 1
• Hemodynamic instability (tachycardia, hypotension) 1
• Fever >38.3°C (101°F) 1
• New visual disturbances 1
• Dizziness or other signs of significant blood loss 1
• Bleeding duration exceeding 30 minutes over a 24-hour period 1

Common Pitfalls to Avoid

• Premature release of compression before the full 10–15 minutes—this is the most common error leading to treatment failure 1
• Bilateral simultaneous septal cautery—markedly increases septal perforation risk 1
• Routine discontinuation of anticoagulation before attempting local hemostatic measures—increases thrombotic risk unnecessarily 1
• Aggressive acute blood-pressure lowering in elderly patients with chronic hypertension—can precipitate end-organ ischemia 1
• Checking if bleeding has stopped during the compression period—interrupts the hemostatic process 1

Special Populations

Hereditary Hemorrhagic Telangiectasia (HHT)

• Screen for HHT in patients with recurrent bilateral nosebleeds or family history by assessing for nasal and oral mucosal telangiectasias 1
• Refer HHT patients to an HHT Center of Excellence for comprehensive multidisciplinary management 1

Elderly Patients

• Elderly patients (≥75 years) should be triaged urgently because age-related anatomic changes increase the likelihood of posterior sources and complications 1
• Posterior epistaxis occurs more often in the elderly and is frequently associated with hypertension, atherosclerosis, and conditions that decrease platelets and clotting function 3

Documentation Requirements

• Record personal and family history of bleeding disorders (von Willebrand disease, hemophilia, easy bruising) 1
• Document all anticoagulant and antiplatelet agents, including NSAIDs, aspirin, clopidogrel, and direct oral anticoagulants 1
• Note intranasal drug use (recreational inhalants, nasal corticosteroids) 1
• Document outcomes within 30 days for patients treated with nasal packing, surgical ligation, or embolization 1